At the 2024 Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, and affinity/kinetics determination using various biophysical techniques, as well as paratope and epitope mapping …Read More >

Psoriasis is a chronic autoimmune skin disease characterized by abnormal keratinocyte proliferation and infiltration of inflammatory cells.  The absence of a suitable animal model that accurately mimics the complex phenotype of psoriasis in humans has hindered the development of promising therapeutics to treat this condition. At SITC 2024, WuXi AppTec presented a poster showcasing the …Read More >

Vitiligo is an autoimmune disorder characterized by the progressive destruction of melanocytes in the skin. This condition is driven by the infiltration of endogenous autoreactive CD8+ T cells, which target and destroy melanocytes, resulting in the clinical manifestation of skin depigmentation. As a common acquired skin disease with no highly effective treatments, there is an …Read More >

Currently, there is a lack of efficient experimental strategies to collect high-quality proteome level data for protein-ligand interactions (PLIs).  At the 2024 ML Drug Discovery Symposium, WuXi AppTec presented a poster showcasing our advanced DELvision database, representing the first use of DNA-encoded library (DEL) technology for establishing a protein-DEL interaction database. The authors demonstrate how …Read More >

Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. This technology is enabling researchers to pursue targets that were previously considered undruggable and to address the resistance issue of small molecule inhibitors. Since 2016, WuXi AppTec has built a comprehensive TPD discovery …Read More >

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key therapeutic strategy for treating advanced metastatic prostate cancer. While AR antagonists like enzalutamide can significantly improve survival in prostate cancer patients, resistance often develops over time, largely driven by treatment-induced mutations within the ligand-binding domain …Read More >

Toll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by specific ligands, TLR8 can trigger potent antiviral responses. Development of an in vivo preclinical model has the potential to greatly accelerate research focused on new anti-HBV agents.  However, rodent TLR8 is unresponsive to human TLR8 …Read More >

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides a comprehensive platform to support the discovery of mRNA drugs.  Our services include mRNA design and production, assessment of mRNA delivery systems, in vitro evaluation, and determination of in vivo efficacy and biodistribution. At AACR …Read More >

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to new applications, including the discovery of bifunctional affinity ligands historically considered difficult to develop. At the 2024 Gordon Research Conference, WuXi AppTec presented a poster describing how DEL can enable the rapid discovery of novel …Read More >